Patents Assigned to Oxxon Therapeutics Limited
  • Publication number: 20090191237
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Application
    Filed: August 4, 2008
    Publication date: July 30, 2009
    Applicant: Oxxon Therapeutics Limited
    Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Patent number: 7514087
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumor antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: April 7, 2009
    Assignee: Oxxon Therapeutics Limited
    Inventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Patent number: 7407661
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: August 5, 2008
    Assignee: Oxxon Therapeutics Limited
    Inventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Patent number: 7384643
    Abstract: Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the CXC group.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: June 10, 2008
    Assignee: Oxxon Therapeutics Limited
    Inventors: Geoffrey Smith, Aylwin Ng